Anika Therapeutics, Inc.
ANIK Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 27, 2026
$21.35
KIRA · Stoqly’s AI analyst, in plain words
- Anika Therapeutics, Inc. had $113M of revenue in fiscal 2025, down 5.9% on the year before. Over five years, revenue changed −2.9% a year on average.
- Its operating margin was −9.8%, down 5.5 pts: of every 100 in sales, about −10 is left after running the business.
- Anika Therapeutics, Inc. lost $10.9M in fiscal 2025.
- Free cash flow was $4.4M in fiscal 2025, 3.9% of revenue.
- Anika Therapeutics, Inc. returned $9.5M to shareholders in fiscal 2025, 217% of free cash flow. The diluted share count fell 2.6%.
Market cap
$293M
P/E
—
Revenue
$113M
Net income
−$10.9M
Free cash flow
$4.4M
Operating margin
−9.8%
Anika Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−5.9%
No. Sales fell 5.9% last year.
Does it make a profit?
−9.6%
No. It lost money last year.
Does profit turn into cash?
3.9%
Partly. 3.9% of sales ends up as free cash.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Anika Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 3, 2026
- Legal name
- Anika Therapeutics, Inc.
- CIK
- 0000898437
Anika Therapeutics, Inc. · ANIK
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $148M | $114M | $121M | $120M | $113M |
| Revenue growth | 13.3% | −23.0% | 6.1% | −0.7% | −5.9% |
| Gross margin | 56.1% | 64.3% | 68.3% | 63.4% | 56.6% |
| Operating margin | 1.8% | 3.2% | 0.7% | −4.3% | −9.8% |
| Net income | $4.1M | −$14.9M | −$82.7M | −$56.4M | −$10.9M |
| Net margin | 2.8% | −13.1% | −68.4% | −47.0% | −9.6% |
| Diluted EPS | $0.28 | −$1.02 | −$5.64 | −$3.83 | −$0.76 |
| Cash | |||||
| Cash from operations | $8.4M | $4.4M | −$1.8M | $5.4M | $11.2M |
| Capital expenditure | $5.1M | $7.5M | $5.4M | $7.7M | $6.8M |
| Free cash flow | $3.3M | −$3.1M | −$7.2M | −$2.3M | $4.4M |
| FCF margin | 2.2% | −2.7% | −6.0% | −1.9% | 3.9% |
| Share buybacks | $0.0M | $0.0M | $5.0M | $10.9M | $9.5M |
| Share count change | 2.9% | 1.0% | −0.9% | 0.4% | −2.6% |
| Debt and strength | |||||
| Cash and short-term investments | $124M | $121M | $95.1M | $79.2M | $81.2M |
| Shareholders' equity | $287M | $286M | $212M | $154M | $143M |
| Current ratio | 5.7x | 6.1x | 5.3x | 4.9x | 4.7x |
| Returns and quality | |||||
| Return on equity | 1.5% | −5.2% | −33.2% | −30.8% | −7.3% |
| Return on tangible equity | 2.1% | −7.3% | −40.9% | −39.1% | −8.1% |
| Piotroski F-score | 7 | 4 | 4 | 4 | 5 |
| Altman Z'' | 9.8 | 9.4 | 8.6 | 7.2 | 6.7 |
Insiders bought, 12 months
$0.3M
3 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Anika Therapeutics, Inc. · ANIK
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $21.35 a share, the company is worth $293M.
Source: SEC EDGAR XBRL filings (CIK 0000898437). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.